Therapy for localized Ewing's sarcoma of bone

Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 G...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 1989-02, Vol.7 (2), p.208-213
Hauptverfasser: Hayes, F A, Thompson, E I, Meyer, W H, Kun, L, Parham, D, Rao, B, Kumar, M, Hancock, M, Parvey, L, Magill, L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 213
container_issue 2
container_start_page 208
container_title Journal of clinical oncology
container_volume 7
creator Hayes, F A
Thompson, E I
Meyer, W H
Kun, L
Parham, D
Rao, B
Kumar, M
Hancock, M
Parvey, L
Magill, L
description Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years).
doi_str_mv 10.1200/JCO.1989.7.2.208
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15561583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15561583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-1946c0bb98222304d61382d81052dbf2d988994bcfd05b6c39e2640a6f3e7e863</originalsourceid><addsrcrecordid>eNo9kD1PwzAYhC0EKqWwsyBlQDAl2K9jxx5RVb5UqUuR2CzHsdtUSV3sRlX59aRqYbrhnrvhQeiW4IwAxk8f41lGpJBZkUEGWJyhIWFQpEXB2Dka4oJCSgT9ukRXMa4wJrmgbIAGIHuM8iFK50sb9GafOB-Sxhvd1D-2Sia7er14jEnUwfhWJ94lpV_ba3ThdBPtzSlH6PNlMh-_pdPZ6_v4eZoayvJtSmTODS5LKQCA4rzihAqoBMEMqtJBJYWQMi-NqzAruaHSAs-x5o7awgpOR-jh-LsJ_ruzcavaOhrbNHptfRcVYYwTJmgP4iNogo8xWKc2oW512CuC1cGQ6g2pgyFVKFC9oX5yd_ruytZW_4OTkr6_P_bLerHc1cGq2Oqm6WlQK-P_bn4BAZhruA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15561583</pqid></control><display><type>article</type><title>Therapy for localized Ewing's sarcoma of bone</title><source>MEDLINE</source><source>American Society of Clinical Oncology Journals</source><source>Journals@Ovid Complete</source><creator>Hayes, F A ; Thompson, E I ; Meyer, W H ; Kun, L ; Parham, D ; Rao, B ; Kumar, M ; Hancock, M ; Parvey, L ; Magill, L</creator><creatorcontrib>Hayes, F A ; Thompson, E I ; Meyer, W H ; Kun, L ; Parham, D ; Rao, B ; Kumar, M ; Hancock, M ; Parvey, L ; Magill, L</creatorcontrib><description>Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years).</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.1989.7.2.208</identifier><identifier>PMID: 2915236</identifier><language>eng</language><publisher>United States: American Society of Clinical Oncology</publisher><subject>Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Neoplasms - pathology ; Bone Neoplasms - therapy ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Male ; Neoplasm Recurrence, Local ; Patient Compliance ; Prognosis ; Remission Induction ; Risk Factors ; Sarcoma, Ewing - pathology ; Sarcoma, Ewing - secondary ; Sarcoma, Ewing - therapy</subject><ispartof>Journal of clinical oncology, 1989-02, Vol.7 (2), p.208-213</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-1946c0bb98222304d61382d81052dbf2d988994bcfd05b6c39e2640a6f3e7e863</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3729,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2915236$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayes, F A</creatorcontrib><creatorcontrib>Thompson, E I</creatorcontrib><creatorcontrib>Meyer, W H</creatorcontrib><creatorcontrib>Kun, L</creatorcontrib><creatorcontrib>Parham, D</creatorcontrib><creatorcontrib>Rao, B</creatorcontrib><creatorcontrib>Kumar, M</creatorcontrib><creatorcontrib>Hancock, M</creatorcontrib><creatorcontrib>Parvey, L</creatorcontrib><creatorcontrib>Magill, L</creatorcontrib><title>Therapy for localized Ewing's sarcoma of bone</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patient Compliance</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Risk Factors</subject><subject>Sarcoma, Ewing - pathology</subject><subject>Sarcoma, Ewing - secondary</subject><subject>Sarcoma, Ewing - therapy</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kD1PwzAYhC0EKqWwsyBlQDAl2K9jxx5RVb5UqUuR2CzHsdtUSV3sRlX59aRqYbrhnrvhQeiW4IwAxk8f41lGpJBZkUEGWJyhIWFQpEXB2Dka4oJCSgT9ukRXMa4wJrmgbIAGIHuM8iFK50sb9GafOB-Sxhvd1D-2Sia7er14jEnUwfhWJ94lpV_ba3ThdBPtzSlH6PNlMh-_pdPZ6_v4eZoayvJtSmTODS5LKQCA4rzihAqoBMEMqtJBJYWQMi-NqzAruaHSAs-x5o7awgpOR-jh-LsJ_ruzcavaOhrbNHptfRcVYYwTJmgP4iNogo8xWKc2oW512CuC1cGQ6g2pgyFVKFC9oX5yd_ruytZW_4OTkr6_P_bLerHc1cGq2Oqm6WlQK-P_bn4BAZhruA</recordid><startdate>19890201</startdate><enddate>19890201</enddate><creator>Hayes, F A</creator><creator>Thompson, E I</creator><creator>Meyer, W H</creator><creator>Kun, L</creator><creator>Parham, D</creator><creator>Rao, B</creator><creator>Kumar, M</creator><creator>Hancock, M</creator><creator>Parvey, L</creator><creator>Magill, L</creator><general>American Society of Clinical Oncology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope></search><sort><creationdate>19890201</creationdate><title>Therapy for localized Ewing's sarcoma of bone</title><author>Hayes, F A ; Thompson, E I ; Meyer, W H ; Kun, L ; Parham, D ; Rao, B ; Kumar, M ; Hancock, M ; Parvey, L ; Magill, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-1946c0bb98222304d61382d81052dbf2d988994bcfd05b6c39e2640a6f3e7e863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patient Compliance</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Risk Factors</topic><topic>Sarcoma, Ewing - pathology</topic><topic>Sarcoma, Ewing - secondary</topic><topic>Sarcoma, Ewing - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayes, F A</creatorcontrib><creatorcontrib>Thompson, E I</creatorcontrib><creatorcontrib>Meyer, W H</creatorcontrib><creatorcontrib>Kun, L</creatorcontrib><creatorcontrib>Parham, D</creatorcontrib><creatorcontrib>Rao, B</creatorcontrib><creatorcontrib>Kumar, M</creatorcontrib><creatorcontrib>Hancock, M</creatorcontrib><creatorcontrib>Parvey, L</creatorcontrib><creatorcontrib>Magill, L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayes, F A</au><au>Thompson, E I</au><au>Meyer, W H</au><au>Kun, L</au><au>Parham, D</au><au>Rao, B</au><au>Kumar, M</au><au>Hancock, M</au><au>Parvey, L</au><au>Magill, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapy for localized Ewing's sarcoma of bone</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>1989-02-01</date><risdate>1989</risdate><volume>7</volume><issue>2</issue><spage>208</spage><epage>213</epage><pages>208-213</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated with nonintensive chemotherapy in combination with surgery or radiation therapy (RT). RT was delivered to limited volumes in a dose dependent on the initial response to induction chemotherapy (30 to 35 Gy v 50 to 55 Gy). Fifty of the 52 patients achieved complete or partial responses with induction chemotherapy, with one nonresponding patient rendered free of tumor with surgery. Fifty patients were evaluable for local control of tumor and overall response to protocol therapy. Seventeen relapses have occurred; three metastatic, four local plus metastatic, and ten local. Two factors predicted worse disease-free survival: high WBC count (P = .03) and size of primary tumor (P = .05). Of the 14 local recurrences, 12 occurred in 28 patients who presented with primary tumors greater than 8 cm in size while only two of 22 patients with lesions less than 8 cm had local recurrence. The Kaplan-Meier estimate of disease-free survival at 3 years is 82% for those with small lesions and 64% for those with larger lesions. Site of primary was of no prognostic value (P = .27). The 5-year survival estimate for all patients is 80% (median time on study, 3.3 years).</abstract><cop>United States</cop><pub>American Society of Clinical Oncology</pub><pmid>2915236</pmid><doi>10.1200/JCO.1989.7.2.208</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0732-183X
ispartof Journal of clinical oncology, 1989-02, Vol.7 (2), p.208-213
issn 0732-183X
1527-7755
language eng
recordid cdi_proquest_miscellaneous_15561583
source MEDLINE; American Society of Clinical Oncology Journals; Journals@Ovid Complete
subjects Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Neoplasms - pathology
Bone Neoplasms - therapy
Child
Child, Preschool
Combined Modality Therapy
Female
Humans
Male
Neoplasm Recurrence, Local
Patient Compliance
Prognosis
Remission Induction
Risk Factors
Sarcoma, Ewing - pathology
Sarcoma, Ewing - secondary
Sarcoma, Ewing - therapy
title Therapy for localized Ewing's sarcoma of bone
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A51%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapy%20for%20localized%20Ewing's%20sarcoma%20of%20bone&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Hayes,%20F%20A&rft.date=1989-02-01&rft.volume=7&rft.issue=2&rft.spage=208&rft.epage=213&rft.pages=208-213&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.1989.7.2.208&rft_dat=%3Cproquest_cross%3E15561583%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15561583&rft_id=info:pmid/2915236&rfr_iscdi=true